DS-1062

4 Reasons AstraZeneca Gave Daiichi Sankyo Another $1 Billion Upfront
Motley Fool
Tue, 07/28/20 - 11:14 am
AstraZeneca
DS-1062
Daiichi Sankyo
AstraZeneca inks $6bn cancer drug deal with Daiichi Sankyo
Pharmaforum
Mon, 07/27/20 - 11:00 am
AstraZeneca
Daiichi Sankyo
DS-1062
antibodies
cancer
Daiichi Sankyo expands DS-1062 study to include patients with triple negative breast cancer
Pharmaceutical Business Review
Thu, 07/2/20 - 11:09 am
Daiichi Sankyo
antibody-drug conjugate
triple negative breast cancer
DS-1062
clinical trials